Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease

MLA

Simone L. Verweij, et al. Atorvastatin Treatment Does Not Abolish Inflammatory Mediated Cardiovascular Risk in Subjects with Chronic Kidney Disease. Dec. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7f509563eacb290f916f7e547ae70a44&authtype=sso&custid=ns315887.

APA

Simone L. Verweij, Sophie J. Bernelot Moens, Renate M. Hoogeveen, Yannick Kaiser, Erik S.G. Stroes, Liffert Vogt, Hein J. Verberne, & Jeffrey Kroon. (2021). Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease.

Chicago

Simone L. Verweij, Sophie J. Bernelot Moens, Renate M. Hoogeveen, Yannick Kaiser, Erik S.G. Stroes, Liffert Vogt, Hein J. Verberne, and Jeffrey Kroon. 2021. “Atorvastatin Treatment Does Not Abolish Inflammatory Mediated Cardiovascular Risk in Subjects with Chronic Kidney Disease,” December. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7f509563eacb290f916f7e547ae70a44&authtype=sso&custid=ns315887.